SM
GENE

Sabby Management’s Genetic Technologies Ltd. GENE Stock Holding History

Sabby Management’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,681
Closed -$48K – 217
2017
Q2 		$48K Sell
2,681
-25,823
-91% -$541K ﹤0.01% 204
2017
Q1 		$678K Sell
28,504
-25,013
-47% -$570K 0.04% 154
2016
Q4 		$1.16M Buy
+53,517
New +$1.48M 0.07% 138

Other funds holding GENE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Sabby Management's GENE Position: Q3 2017 in Review

Sabby Management sold out of Genetic Technologies Ltd. (GENE) in Q3 2017, closing a stake of 2,681 shares — an estimated $48K sold.

Sabby Management first reported a position in GENE in Q4 2016 and held it in 3 quarters. The position peaked at $1.16M in Q4 2016. 10 funds tracked by Wall St. Rank hold GENE as of Q3 2017.

  • Sabby Management reported no remaining Genetic Technologies Ltd. position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 2,681 Genetic Technologies Ltd. shares in Q3 2017, an estimated $48K.
  • Sabby Management first reported a position in Genetic Technologies Ltd. in Q4 2016 and held it in 3 quarters.
  • Sabby Management's Genetic Technologies Ltd. position peaked at $1.16M in Q4 2016.
  • 10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.